Bank of New York Mellon Corp Lowers Holdings in LeMaitre Vascular, Inc. (NASDAQ:LMAT)

Bank of New York Mellon Corp lowered its stake in shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT - Free Report) by 3.3% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 178,747 shares of the medical instruments supplier's stock after selling 6,048 shares during the period. Bank of New York Mellon Corp owned 0.80% of LeMaitre Vascular worth $16,470,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds also recently bought and sold shares of LMAT. DF Dent & Co. Inc. lifted its holdings in LeMaitre Vascular by 26.2% during the third quarter. DF Dent & Co. Inc. now owns 258,767 shares of the medical instruments supplier's stock worth $24,037,000 after buying an additional 53,797 shares during the period. Barclays PLC lifted its holdings in LeMaitre Vascular by 394.5% during the third quarter. Barclays PLC now owns 36,577 shares of the medical instruments supplier's stock worth $3,396,000 after buying an additional 29,180 shares during the period. State Street Corp lifted its holdings in LeMaitre Vascular by 3.6% during the third quarter. State Street Corp now owns 822,085 shares of the medical instruments supplier's stock worth $76,363,000 after buying an additional 28,525 shares during the period. Geode Capital Management LLC lifted its holdings in LeMaitre Vascular by 4.5% during the third quarter. Geode Capital Management LLC now owns 542,523 shares of the medical instruments supplier's stock worth $50,403,000 after buying an additional 23,443 shares during the period. Finally, M&T Bank Corp purchased a new stake in LeMaitre Vascular during the third quarter worth $1,551,000. Hedge funds and other institutional investors own 84.64% of the company's stock.

LeMaitre Vascular Price Performance

NASDAQ LMAT opened at $82.30 on Wednesday. The stock's fifty day moving average price is $95.88 and its 200 day moving average price is $94.86. LeMaitre Vascular, Inc. has a 1 year low of $62.39 and a 1 year high of $109.58. The company has a market cap of $1.86 billion, a price-to-earnings ratio of 44.97, a PEG ratio of 2.22 and a beta of 0.89.

Remove Ads

LeMaitre Vascular (NASDAQ:LMAT - Get Free Report) last released its earnings results on Thursday, February 27th. The medical instruments supplier reported $0.49 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.49. LeMaitre Vascular had a return on equity of 13.15% and a net margin of 19.40%. The firm had revenue of $55.81 million for the quarter, compared to the consensus estimate of $55.99 million. Research analysts expect that LeMaitre Vascular, Inc. will post 1.94 earnings per share for the current year.

LeMaitre Vascular Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, March 27th. Investors of record on Thursday, March 13th will be given a $0.20 dividend. This represents a $0.80 annualized dividend and a dividend yield of 0.97%. This is an increase from LeMaitre Vascular's previous quarterly dividend of $0.16. The ex-dividend date is Thursday, March 13th. LeMaitre Vascular's dividend payout ratio is presently 41.24%.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on LMAT. Lake Street Capital upped their target price on LeMaitre Vascular from $105.00 to $110.00 and gave the stock a "buy" rating in a report on Friday, February 28th. Oppenheimer lowered LeMaitre Vascular from an "outperform" rating to a "market perform" rating in a report on Friday, February 28th. Wells Fargo & Company started coverage on LeMaitre Vascular in a research report on Thursday, February 13th. They set an "equal weight" rating and a $95.00 price target on the stock. StockNews.com downgraded LeMaitre Vascular from a "buy" rating to a "hold" rating in a research report on Friday, December 13th. Finally, Barrington Research downgraded LeMaitre Vascular from an "outperform" rating to a "market perform" rating in a research report on Friday, February 28th. Five equities research analysts have rated the stock with a hold rating, four have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, LeMaitre Vascular has an average rating of "Moderate Buy" and an average price target of $95.25.

LeMaitre Vascular Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.